---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-052877"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2026-08-05T10:02:36+00:00"
generated_at: "2026-08-05T10:10:30.555317+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BeOne Medicines Q2 revenue up 30% to $1.7B; raises FY2026 guidance

## Summary
- Q2 total revenue $1.71B (+30% YoY); BRUKINSA revenue $1.2B (+31% YoY).
- GAAP diluted EPS $2.05; non-GAAP diluted EPS $3.84 (up 71% YoY).
- Raised FY2026 revenue guidance to $6.6-6.8B; GAAP op income $1.0-1.1B.
- Q2 free cash flow $435M (+98% YoY); six-month total revenue $3.22B (+32% YoY).
- CEO cites strong hematology franchise and pipeline momentum.

## SEC filing metadata
- accession: 0001628280-26-052877
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2026-08-05T10:02:36+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/0001628280-26-052877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/bgne-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-052877
- JSON: https://secwatch.observer/filing/0001628280-26-052877.json
- Plain text: https://secwatch.observer/filing/0001628280-26-052877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.